for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG (ADR)

NVS.N

Latest Trade

96.90USD

Change

0.02(+0.02%)

Volume

356,301

Today's Range

96.58

 - 

97.52

52 Week Range

69.31

 - 

99.82

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

GSK, Novartis Announce Collaboration To Support Scientific Research Into Genetic Diversity In Africa

Jan 19 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK AND NOVARTIS ANNOUNCE COLLABORATION TO SUPPORT SCIENTIFIC RESEARCH INTO GENETIC DIVERSITY IN AFRICA.GSK - PROJECT AFRICA GENOMIC RESEARCH APPROACH FOR DIVERSITY AND OPTIMISING THERAPEUTICS WITH COMBINED FUNDING COMMITMENT OF GBP 2.8M OVER 5 YEARS.

Novartis And GSK Collaborate To Support Research Into Genetic Diversity In Africa

Jan 19 (Reuters) - NOVARTIS AG <NOVN.S>::NOVARTIS AND GSK ANNOUNCE COLLABORATION TO SUPPORT SCIENTIFIC RESEARCH INTO GENETIC DIVERSITY IN AFRICA.COMBINED FUNDING COMMITMENT OF GBP 2.8 MILLION (USD 3.6 MILLION) OVER FIVE YEARS.RESEARCHERS BASED AT UNIVERSITIES, SCIENCE COUNCILS AND OTHER PUBLIC RESEARCH ORGANIZATIONS ACROSS AFRICA ARE INVITED TO EXPRESS ‘INTENT TO SUBMIT’ BY MARCH 1, 2021.FINAL AWARD RECIPIENTS ARE EXPECTED TO BE ANNOUNCED BY END OF 2021.PROJECT AFRICA GRADIENT CALLS ON LOCAL RESEARCHERS TO SUBMIT PROPOSALS EXPLORING THE LINK BETWEEN GENETIC DIVERSITY AND RESPONSE TO MALARIA AND TUBERCULOSIS DRUGS IN AFRICAN PATIENTS.

Novartis hives hopeful ligelizumab gets FDA breakthrough therapy tag

Jan 14 (Reuters) - Novartis AG <NOVN.S>::NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU).LIGELIZUMAB IS FIRST TREATMENT TO RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION IN CHRONIC SPONTANEOUS URTICARIA (CSU) IN PATIENTS WITH AN INADEQUATE RESPONSE TO H1-ANTIHISTAMINES.CURRENTLY THERE ARE LIMITED APPROVED THERAPIES FOR PATIENTS WITH CSU, ALSO KNOWN AS CHRONIC IDIOPATHIC URTICARIA (CIU).U.S. REGULATORY FILING IN CSU IS ANTICIPATED IN 2022.

Beigene Announces Collaboration With Novartis

Jan 12 (Reuters) - Beigene <6160.HK>::UNIT ENTERED COLLABORATION AND LICENSE AGREEMENT WITH NOVARTIS PHARMA AG.UNDER AGREEMENT CO TO RECEIVE AN UPFRONT CASH PAYMENT OF US$650 MILLION FROM NOVARTIS.CO ELIGIBLE FOR UP TO US$1.3 BILLION UPON ACHIEVEMENT OF REGULATORY MILESTONES, US$250 MILLION ON SALES MILESTONES.

Siegfried Holding Issues Two Hybrid Convertible Bonds

Dec 28 (Reuters) - SIEGFRIED HOLDING AG <SFZN.S>::SUCCESSFULLY ISSUES TWO HYBRID CONVERTIBLE BONDS IN THE AMOUNT OF 80 MILLION SWISS FRANCS.BONDS ENTITLE EGS BETEILIGUNGEN TO CONVERT THE TOTAL AMOUNT INTO SHARES OF SIEGFRIED HOLDING WITHIN 5 YEARS.IN CASE OF CONVERSION, INCLUDING SHARES ALREADY HELD BY EGS BETEILIGUNGEN , IT WOULD LEAD TO STAKE OF UP TO AROUND 6.6% IN SIEGFRIED.AS OF TODAY, ALL REQUIREMENTS FOR THE FORMAL CLOSING OF THE TRANSACTION WITH NOVARTIS ARE IN PLACE.Further company coverage: <SFZN.S>. (Gdansk Newsroom). ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;)).

Novartis Receives Complete Response Letter From U.S. FDA For Inclisiran

Dec 18 (Reuters) - Novartis AG <NOVN.S>::NOVARTIS RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR INCLISIRAN.FOOD AND DRUG ADMINISTRATION (FDA) HAS NOT RAISED ANY CONCERNS RELATED TO EFFICACY OR SAFETY OF INCLISIRAN.NO ONSITE INSPECTION WAS CONDUCTED OF SINGLE THIRD-PARTY FACILITY IN QUESTION.COMPLETE RESPONSE LETTER IS DUE TO UNRESOLVED FACILITY INSPECTION-RELATED CONDITIONS.IF A FACILITY INSPECTION IS NEEDED, FDA WILL DEFINE APPROACH ONCE SAFE TRAVEL MAY RESUME BASED ON PUBLIC HEALTH NEED AND OTHER FACTORS.CONDITIONS WILL BE CONVEYED TO EUROPEAN MANUFACTURING FACILITY WITHIN 10 BUSINESS DAYS.NOVARTIS-FDA STATED IT CANT APPROVE NDA BY PRESCRIPTION DRUG USER FEE ACT ACTION DATE OF DEC 23 ON UNRESOLVED FACILITY INSPECTION-RELATED CONDITIONS.NOVARTIS-WILL WORK WITH FDA, THIRD-PARTY MANUFACTURING FACILITY IN EUROPE TO COMPLETE REVIEW, BRING POTENTIAL FIRST-IN-CLASS SIRNA TO PATIENTS IN US.

Novartis Pharmaceuticals Canada Inc - Health Canada Approved Zolgensma For Treatment Of Pediatric Patients With 5Q Spinal Muscular Atrophy (SMA)1

Dec 16 (Reuters) - Novartis AG <NOVN.S>::NOVARTIS PHARMACEUTICALS CANADA INC - HEALTH CANADA APPROVED ZOLGENSMA FOR TREATMENT OF PEDIATRIC PATIENTS WITH 5Q SPINAL MUSCULAR ATROPHY (SMA)1.

Novartis Announces Positive Results From Beovu Trial In Patients With Diabetic Macular Edema

Dec 15 (Reuters) - Novartis AG <NOVN.S>::NOVARTIS REPORTS POSITIVE TOPLINE RESULTS FROM SECOND PHASE III TRIAL OF BEOVU® IN PATIENTS WITH DIABETIC MACULAR EDEMA.NOVARTIS REPORTS POSITIVE TOPLINE RESULTS FROM SECOND PHASE III TRIAL OF BEOVU® IN PATIENTS WITH DIABETIC MACULAR EDEMA.IN PHASE III KESTREL STUDY, BEOVU (BROLUCIZUMAB 6 MG) ACHIEVED ITS PRIMARY ENDPOINT OF NON-INFERIORITY TO AFLIBERCEPT 2 MG IN CHANGE IN BEST-CORRECTED VISUAL ACUITY (BCVA) AT YEAR ONE.IN A SECONDARY ENDPOINT, MORE THAN HALF OF BEOVU PATIENTS IN 6 MG ARM WERE MAINTAINED ON A THREE-MONTH DOSING INTERVAL THROUGH YEAR ONE, FOLLOWING LOADING PHASE.SIGNIFICANT IMPROVEMENT WITH BEOVU 6 MG IN CHANGE OF CENTRAL SUBFIELD THICKNESS (CST) FROM BASELINE OVER PERIOD OF WEEK 40 THROUGH WEEK 52 WAS OBSERVED.BEOVU DEMONSTRATED AN OVERALL WELL-TOLERATED SAFETY PROFILE.NOVARTIS INTENDS TO SUBMIT DATA FROM KESTREL, TOGETHER WITH DATA FROM PIVOTAL PHASE III KITE(2) STUDY IN DME, TO HEALTH AUTHORITIES IN H1 2021.

Incyte Corp Says Initial Data Show That Treatment With Ruxolitinib Did Not Prevent Complications In Patients With Covid-19 Associated Cytokine Storm

Dec 14 (Reuters) - Incyte Corp <INCY.O>::INITIAL DATA SHOW THAT TREATMENT WITH RUXOLITINIB DID NOT PREVENT COMPLICATIONS IN PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM.THERE WAS NO CLINICALLY RELEVANT BENEFIT OBSERVED AMONG SECONDARY AND EXPLORATORY ENDPOINTS IN PHASE 3 STUDY.INCYTE - RESULTS OF THIS STUDY DO NOT AFFECT OTHER ONGOING NON-COVID-19 RELATED RUXOLITINIB CLINICAL TRIALS OR APPROVED USES OF RUXOLITINIB.INCYTE - RUXCOVID STUDY IS COMPLETE. DATA WILL BE FURTHER ANALYZED TO DETERMINE ANY IMPACT ON OTHER STUDIES OF RUXOLITINIB IN COVID-19 PATIENTS.

Novartis Announces EU Approval For Leqvio

Dec 11 (Reuters) - Novartis AG <NOVN.S>::NOVARTIS RECEIVES EU APPROVAL FOR LEQVIO®* (INCLISIRAN), A FIRST-IN-CLASS SIRNA TO LOWER CHOLESTEROL WITH TWO DOSES A YEAR**.APPROVAL IS BASED ON A ROBUST CLINICAL DEVELOPMENT PROGRAM DEMONSTRATING EFFECTIVE AND SUSTAINED LDL-C REDUCTION OF UP TO 52% IN PATIENTS WITH ELEVATED LDL-C DESPITE MAXIMALLY TOLERATED STATIN THERAPY.Further company coverage: NOVN.S. (Berlin Speed Desk). ((berlin.newsroom(at)thomsonreuters.com; +49 30 2201 33599;)).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up